OptiMedica has received significant financial backing and business advice from several highly regarded venture capital firms. These firms have a stellar track record of supporting entrepreneurs in building successful companies.
Kleiner Perkins Caufield & Byers
Kleiner Perkins Caufield & Byers (KPC&B) is committed to helping entrepreneurs build sustainable technology businesses. For over 30 years, KPC&B has invested in hundreds of market-defining ventures, many of which have gone public or achieved success through mergers and acquisitions. The firm is constantly on the lookout for ideas with the promise to invent new business categories or radically alter existing ones. Its focus is on new technologies and new applications of technology that will drive high-impact change.
Alloy Ventures has a rich history of early-stage venture investing that has produced many industry-leading companies. Since 1977, partners of Alloy Ventures have helped start and cultivate, over several economic cycles, more than 200 successful companies in the fields of information technology and life sciences. Alloy Ventures has more than $1 billion under management.
DAG Ventures is a venture capital partnership investing in and helping outstanding entrepreneurs create leading, long-term companies across a range of markets. With roots from the 1980s in cable TV, infrastructure, media and wireless industries, the partnership today is privileged to work with world-class entrepreneurs as they build tomorrow’s leaders in the information technology, energy and life science sectors.
BlackRock is one of the world’s leading asset management firms. Its Private Equity Partners (BlackRock PEP) group, which has invested in OptiMedica, was founded in 1999 to manage diversified private equity portfolios inclusive of primary funds, secondary opportunities and direct co-investments. PEP has a global reach and operational depth managing investments in private equity, venture capital, and certain other private investment sectors. Its investment process, implemented through insightful fundamental due diligence and research, is designed to identify successful funds and direct co-investment opportunities through an assorted range of industries, geographies and investment strategies. The BlackRock PEP team includes 53 professionals located in New York; Princeton, N.J.; Durham, N.C.; and London.
EDB Investments’ subsidiary Bio*One Capital is a leading, biomedical sciences dedicated investment management company in Asia with a global presence. Investments are focused on promising and innovative international biomedical companies where Bio*One Capital can play a value-adding role in bridging and supporting growth strategies in Asia through Singapore. Bio*One Capital oversees a portfolio of over 50 companies in the United States, Europe, Singapore and Asia.